Posted inHematology-Oncology news
Recombinant ADAMTS13 Therapy Demonstrates Superior Efficacy and Safety Over Plasma-Based Therapy in Congenital Thrombotic Thrombocytopenic Purpura: Final Phase 3 Trial Results
Final phase 3 trial analysis confirms recombinant ADAMTS13 (rADAMTS13) provides effective prophylaxis with fewer acute and subacute TTP events and better safety than plasma-based therapy in congenital TTP patients.
